Warrant No:______ THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED,...Warrant Agreement • May 18th, 2004 • Ym Biosciences Inc • Ontario
BY-License Agreement • May 18th, 2004 • Ym Biosciences Inc • Saskatchewan
EXHIBIT 4.11 ASSIGNMENT AND ASSUMPTION AGREEMENT THIS AGREEMENT made as of the 22nd day of November, 1995 B E T W E E N: YORK MEDICAL INC. ("York") - and - CIMYM INC. ("Cimym") WHEREAS: A. Pursuant to a licensing agreement (the "Licensing Agreement")...Assignment and Assumption Agreement • May 18th, 2004 • Ym Biosciences Inc • Ontario
EXHIBIT 99.2 MERGER AGREEMENTMerger Agreement • May 3rd, 2005 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
EXHIBIT 99.4 ESCROW AGREEMENT THIS AGREEMENT is made as of the 2nd day of May, 2005, B E T W E E N: YM BIOSCIENCES INC., a corporation existing under the laws of the Province of Nova Scotia ("YM")Escrow Agreement • May 3rd, 2005 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
EXHIBIT 99.7 ASSIGNMENT AGREEMENT THIS AGREEMENT made as of the 2nd day of May, 2005 BETWEEN: EASTERN TECHNOLOGY SEED INVESTMENT FUND LIMITED PARTNERSHIP, a limited partnership formed under the laws of the Province of Ontario (hereinafter called the...Assignment Agreement • May 3rd, 2005 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
Exhibit 4.6 LICENSING AGREEMENT This Agreement is made this 3rd day of May, 1995 between Yorkton Medical Inc., a corporation incorporated under the laws of Ontario and located at The Exchange Tower, 2 First Canadian Place, Suite 3640, Toronto,...Licensing Agreement • May 18th, 2004 • Ym Biosciences Inc • Ontario
EXHIBIT 4.4Collaboration Agreement • September 24th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • Manitoba
YM BIOSCIENCES INC. And CIBC MELLON TRUST COMPANY As Rights Agent SHAREHOLDER RIGHTS PLAN AGREEMENTShareholder Rights Plan Agreement • December 11th, 2007 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
THIS AGREEMENT dated as of the 22nd day of October, 2007 between YM BioSciences Inc. (the “Corporation”), a corporation continued under the Companies Act (Nova Scotia), and CIBC Mellon Trust Company, a trust company incorporated under the laws of Canada, as Rights Agent (the “Rights Agent”), which term shall include any successor Rights Agent hereunder.
Exhibit 4.3 (1) CIMYM, INC. (2) CIMAB S.A. ANDDevelopment and License Agreement • September 24th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • London
EXHIBIT 4.17Assignment and Assumption Agreement • May 18th, 2004 • Ym Biosciences Inc
We refer to the assignment and assumption agreement dated as of November 22, 1995 among CBQYM INC. and York Medical Inc. ("YMI") pursuant to which YMI assigned to CBQYM INC. all of YMI's right, title and interest in and to the Licensing Agreement (as defined therein).
EXHIBIT 99.3 AMALGAMATION AGREEMENT THIS AMALGAMATION AGREEMENT is made as of the 2nd day of May, 2005. AMONG: YM BIOSCIENCES INC. ("YM") AND: 2069044 ONTARIO LIMITED ("Subco") AND: DELEX THERAPEUTICS INC. ("Delex") WHEREAS: A. Pursuant to a merger...Amalgamation Agreement • May 3rd, 2005 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
RECITALSJoint Venture Shareholders' Agreement • May 18th, 2004 • Ym Biosciences Inc
Between: York Medical Inc.("YM"), a company incorporated under the laws of the Province of Ontario, Canada, CIMYM Inc., a company incorporated under the laws of Barbados ("CIMYM") and CIMAB S.A. ("CIMAB") a Cuban company incorporated under the laws of the Republic of Cuba, representing Centro de Inmunologia Molecular ("CIM").
ARRANGEMENT AGREEMENT AMONG GILEAD SCIENCES, INC. - AND - 3268218 NOVA SCOTIA LIMITED - AND – YM BIOSCIENCES INC. DECEMBER 12, 2012Arrangement Agreement • December 12th, 2012 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
WHEREAS the Parent desires to acquire all of the Common Shares (as hereinafter defined) through its wholly-owned subsidiary, the Purchaser;
US Placement Agent Warrant] PLACEMENT AGENT WARRANT NO. US - ______ THIS WARRANT AND THE SECURITIES REPRESENTED HEREBY OR ACQUIRABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE...Placement Agent Warrant • May 18th, 2004 • Ym Biosciences Inc • New York
CLINICAL RESEARCH SERVICES AGREEMENT BETWEEN YM BIOSCIENCES, INC. AND PHARM- OLAM INTERNATIONAL LTD.Clinical Research Services Agreement • September 24th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
EXHIBIT 4.20 CONFIDENTIALLicense, Development, Manufacturing and Supply Agreement • September 24th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • England and Wales
9,436,471 Shares YM BIOSCIENCES INC. Common Shares (without nominal or par value) PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • February 17th, 2006 • Ym Biosciences Inc • Pharmaceutical preparations • New York
EXHIBIT 4.18 EXCLUSIVE INTERNATIONAL SALES, MARKETING MANUFACTURING AND ADMINISTRATIVE AGREEMENT (hereinafter called the "Agreement")Exclusive International Sales, Marketing, Manufacturing and Administrative Agreement • May 18th, 2004 • Ym Biosciences Inc • Ontario
EXHIBIT 10.24 SECOND LEASE AMENDING AGREEMENT THIS AGREEMENT made as of the 1st day of March, 2005 BETWEEN: RT ELEVENTH PENSION PROPERTIES LIMITED (the "Landlord") - and - DELEX THERAPEUTICS INC. (the "Tenant") RECITALS: A. By a lease dated the 29th...Second Lease Amending Agreement • June 30th, 2005 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
AGREEMENT THIS AGREEMENT, effective November 2, 2000, is entered intoCollaboration Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Manitoba
EXHIBIT 4.9 LEASE AMENDING AND EXTENSION AGREEMENT THIS AGREEMENT made as of the 15TH DAY OF JANUARY, 2003. BETWEEN:Lease Amending and Extension Agreement • May 18th, 2004 • Ym Biosciences Inc
MASTER SERVICES AGREEMENTMaster Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
This Master Services Agreement ("Agreement") is entered into as of May 17th, 2007 (the "Effective Date") by and between YM Biosciences Inc., a Canadian corporation with an office at 5045 Orbitor Drive, Bldg. 11, Suite 400, Mississauga, Ontario L4W 4Y4 (collectively with its Affiliates hereinafter the "YMB") and Allphase Clinical Research Services Inc., having offices at 19 Camelot Drive, Ottawa, Ontario, K2G 5W6 (collectively with its Affiliates hereinafter "ALLPHASE"). YMB and ALLPHASE are referred to singly as "Party" and jointly as "Parties" throughout this Agreement.
YM BIOSCIENCES INC. 7,750,000 Common Shares Controlled Equity Offeringsm Sales AgreementSales Agreement • April 26th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • New York
YM BIOSCIENCES INC. (the “Company”), a corporation continued under the Nova Scotia Companies Act (the “NSCA”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“CF&Co”), as follows:
Agreement Implementation agreement YM BioSciences Inc. Cytopia Limited rodd.levy@freehills.com 101 Collins Street Melbourne VIC 3000 Australia GPO Box 128A Melbourne VIC 3001 Australia Sydney Melbourne Perth Brisbane Singapore Telephone +61 3 9288...Implementation Agreement • October 8th, 2009 • Ym Biosciences Inc • Pharmaceutical preparations • Victoria
YM may not rely on the words or conduct of any Scheme Shareholder as a waiver of any right unless the waiver is in writing and signed by the Scheme Shareholder granting the waiver.
AGREEMENT AND PLAN OF MERGER BY AND AMONG YM BIOSCIENCES INC., YM BIOSCIENCES USA INC., YM BIOSCIENCES U.S. OPERATIONS INC., EXIMIAS PHARMACEUTICAL CORPORATION AND ORBIMED ADVISORS, LLC, AS STOCKHOLDER REPRESENTATIVE April 13, 2006Merger Agreement • September 22nd, 2008 • Ym Biosciences Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into on April 13, 2006, by and among YM BioSciences Inc., a corporation existing under the laws of Nova Scotia, Canada (“Acquiror”), YM BioSciences USA Inc., a Delaware corporation and wholly-owned subsidiary of Acquiror, (“YM BioSciences USA”), YM BioSciences U.S. Operations Inc., a Delaware corporation and wholly-owned subsidiary of YM BioSciences USA (“Merger Sub”), Eximias Pharmaceutical Corporation, a Delaware corporation (“Target”), and OrbiMed Advisors, LLC on behalf of the Series D Stockholders (in such capacity referred to as the “Stockholder Representative”). Certain capitalized terms used in this Agreement are defined in Exhibit A hereto.
CLINICAL RESEARCH SERVICES AGREEMENT BETWEEN YM BIOSCIENCES, INC. AND PHARM- OLAM INTERNATIONAL LTD. YB1002-203TaxotereClinical Research Services Agreement • September 22nd, 2008 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
This Clinical Research Services Agreement (this Agreement) is made and entered into effective as of 10 December 2004 (the “Effective Date”), by and between YM BIOSCIENCES, INC. (hereafter “YM”), a Canadian corporation, with its principal office at 5045 Orbitor Drive, Building 11, Suite 400, Mississauga, Ontario L4W 4Y4, Canada, and PHARM-OLAM INTERNATIONAL Ltd. (hereafter “POI”), a Texas limited partnership, with its principal office at 450 N Sam Houston Parkway, Suite 250, Houston, TX 77060, United States.
CLINICAL RESEARCH SERVICES AGREEMENT BETWEEN YM BIOSCIENCES, INC. AND PHARM- OLAM INTERNATIONAL LTD. YB1002-203TaxotereClinical Research Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
This Clinical Research Services Agreement (this Agreement) is made and entered into effective as of 10 December 2004 (the “Effective Date”), by and between YM BIOSCIENCES, INC. (hereafter “YM”), a Canadian corporation, with its principal office at 5045 Orbitor Drive, Building 11, Suite 400, Mississauga, Ontario L4W 4Y4, Canada, and PHARM-OLAM INTERNATIONAL Ltd. (hereafter “POI”), a Texas limited partnership, with its principal office at 450 N Sam Houston Parkway, Suite 250, Houston, TX 77060, United States.
and License Agreement Relating to Nimotuzumab (TheraCIM h-R3)License Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • London
AGREEMENT OF LEASE BETWEEN CHESTERBROOK PARTNERS, LP AND YM BIOSCIENCES USA, INC. SUITES 200 and 220 701 LEE ROAD CHESTERBROOK CORPORATE CENTER® TREDYFFRIN TOWNSHIP CHESTER COUNTY PENNSYLVANIALease Agreement • September 22nd, 2008 • Ym Biosciences Inc • Pharmaceutical preparations • Pennsylvania
Work Order #1 Dated November 9, 2007Master Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations
The services described herein will be provided in accordance with the terms and conditions of the Master Services Agreement, dated August 24, 2007, between AAIPharma Inc., on behalf of itself and its subsidiaries (collectively, ‘AAIPharma’) and YM Biosciences USA Inc. (hereinafter referred to as “YMB USA”).
MASTER SERVICES AGREEMENTMaster Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations
This Master Services Agreement ("Agreement") is entered into as of August 24th, 2007 (the "Effective Date") by and between YM Biosciences USA Inc., a corporation incorporated in Delaware located at 701 Lee Road, Suite 201, Wayne, PA 19087 (hereinafter “YMB USA USA”) and AAIPharma Inc., having offices at 2320 Scientific Drive, Wilmington, North Carolina 28405, including its subsidiaries (“AAIPharma”). YMB USA USA and AAIPharma are referred to singly as "Party" and jointly as "Parties" throughout this Agreement.
YM BIOSCIENCES INC. (a Nova Scotia corporation) 35,000,000 Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • February 24th, 2012 • Ym Biosciences Inc • Pharmaceutical preparations • New York
This opinion is given as of the date hereof, and we assume no obligation to update or supplement this opinion to reflect any facts or circumstances which may hereafter occur or come to our attention or to assess the likelihood or effect of any event. including any proceeding or appeal which hereafter may be initiated by or before OFAC, or any federal or state court, or any changes in laws, rules, or regulations, or the interpretation of’ such, which may hereafter occur.
ContractDevelopment and Licence Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • London
And Development and License Agreement Relating to Nimotuzumab (TheraCIM h-R3)Development and License Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • London
